Sentences with phrase «immune response to cancer»

Treatment vaccines treat an existing cancer by strengthening the body's natural immune response to the cancer.

I have successfully integrated laboratory and clinical teams to better understand immune responses to cancer and develop breakthrough therapies based on this knowledge.

We are particularly interested in leverage our interdisciplinary expertise in polymer chemistry, nanomedicine, drug delivery and immunobiology to innovate new approaches to modulate the tumor microenvironment and enhance cellular immune responses to cancer vaccines.

These drugs work by targeting the PDL - 1 receptor — a known immunotherapy biomarker for lung and other cancers — to boost immune responses to the cancer.

SynNotch engineered T cells are also versatile in that they can either be used drive a potent immune response to cancer or suppress an immune response in an autoimmune setting,» he said.

In cases where there are lots of T cells in the vicinity of a tumor, or where tumor cells have undergone large numbers of mutations, which creates additional targets for immune sentries, T cells will signal a full - fledged immune response to the cancer.

The results show that generation of an optimal immune response to cancer requires cooperation between two types of memory T cell — one circulating in the blood and the other resident in tissues — that can be reactivated with current immunotherapy strategies.

During her time as a postdoc studying immune response to cancer at NCI, she met the other founders of NPA and helped build the organization.

The team reasoned that they might be able to use the switch gene to activate not just tyrosinase, but a range of other genes too — for example, genes that would stimulate a stronger immune response to cancer cells.

In the 1990s, he and members of his laboratory, including CRI - funded scientists Madhav Dhodapkar, M.D., and Nina Bhardwaj, M.D., Ph.D., published the first studies showing that DCs could be used to elicit a reliable immune response to cancer.

Both of these programs incorporate the three key elements of dendritic cells, telomerase and LAMP to stimulate immune responses to cancer cells.

Our AST - VAC immunotherapy programs employ three common elements of dendritic cells, telomerase antigen, and the LAMP signal sequence to stimulate robust and specific immune responses to cancer cells (Figure 1).

«By targeting a genetic pathway in cells that ordinarily restrain the immune response to cancer, we may be able to convert them into cancer fighters.

«We've uncovered a potential new approach to modulate the immune response to cancer,» says Dr. Ohashi.

T - cells are crucial to the body's immune response to cancer, both endogenously and following therapeutic intervention.

Immuno - oncology is a rapidly growing field of cancer treatment based on understanding the body's immune response to cancer.

Cancer Immunity was an open access, peer - reviewed journal of the Cancer Research Institute (CRI) that published laboratory and clinical research papers on the immune response to cancer until 2013.

In March 2016, the Felsher lab at Stanford University reported that in a mouse model of T - cell acute lymphoblastic leukaemia (T - ALL), MYC up - regulates the «invisibility» ligand PD - L1, thwarting the immune response to the cancer.

Conversely, however, there is growing proof that limiting radiation therapy to certain areas may also benefit the immune response to cancer.

These drugs «take the brakes off» the immune response to cancer, and represent a truly breakthrough way of treating cancer.

It is co-opted by tumors to shut down an immune response to cancer cells.

CTLA - 4 inhibitors belong to the family of «immune checkpoint inhibitors» — a type of immunotherapy that helps in controlling the body's immune response to cancer.

PD - 1 / PD - L1 inhibitors belong to the family of «immune checkpoint inhibitors» — a type of immunotherapy that helps in controlling the body's immune response to cancer.

As the cancer field saw successes with immunotherapies that could boost patients» immune responses to cancer, Swanton turned to studying how heterogeneity within a tumor influences its interaction with the immune system.

«The challenge now is to maximize the effectiveness of cancer vaccines such as Provenge by incorporating all we have learned in recent years about the immune response to cancer and cancer vaccine development, converting the four - month survival advantage of Provenge - vaccinated patients into prolonged — even lifelong — control of the disease.»

Like others, he was hoping that tramping on the accelerators might mobilize the immune response to cancer — a latter - day version of Coley's toxin.